VivoSeq
Other

Vinorelbine

0

Pipeline Programs↗

0

Active Trials↗

7

Companies Involved↗

Vinorelbine is an early-stage landscape with 0 programs across 7 companies. The most active players are Sanofi, AstraZeneca, Novartis.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalP

Pierre Fabre Pharma GmbH

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

15

clinical trials

Completed10 · 67%
Unknown status3 · 20%
Terminated2 · 13%

Clinical Trials

Trial Activity

15 trials

Efficacy Study of GEMOX Combination and Vinorelbine in NSCL Patients
Completed·Sanofi logoSanofi·Phase 2·NCT00271271·40 enrolled
Phase II Iressa Versus Vinorelbine (INVITE)
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT00256711·192 enrolled
Lapatinib in Combination With Vinorelbine
Completed·Novartis logoNovartis·Phase 2·NCT01013740·112 enrolled
Lapatinib in Combination With Vinorelbine
Completed·GSK logoGSK·Phase 2·NCT01128543·29 enrolled
Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT00906698·55 enrolled
Vinorelbine for Recurrent ACLC
Completed·CChildren's Cancer Group, China·Phase 2·NCT03397953·20 enrolled
Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria
Completed·PPierre Fabre Pharma GmbH·N/A·NCT02619929·108 enrolled
Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom
Completed·EEl Kendi Pharmaceuticals Manufacturing Company·Phase 3·NCT03413579·37 enrolled
Vinorelbine and XR9576 to Treat Cancer
Completed·National Cancer Institute (NCI)·Phase 1·NCT00001944·30 enrolled
Vinorelbine for Recurrent ALCL-2017
Completed·CChildren's Cancer Group, China·Phase 2·NCT03443128·20 enrolled
BIBW 2992 (Afatinib) and Vinorelbine
Terminated·UUniversity of Magdeburg·Phase 2·NCT01531764·2 enrolled
Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function
Terminated·—·Phase 2/3·NCT00169104·23 enrolled
Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse
Unknown status·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT00180947·210 enrolled
GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial
Unknown status·IIRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy·Phase 2·NCT02319577·80 enrolled
Almonertinib Plus Metronomic Oral Vinorelbine
Unknown status·FFujian Cancer Hospital·N/A·NCT05663177·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)